Arvinas Inc
NASDAQ:ARVN
Arvinas Inc
Revenue
Arvinas Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arvinas Inc
NASDAQ:ARVN
|
Revenue
$78.5m
|
CAGR 3-Years
53%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$55.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$35.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is Arvinas Inc's Revenue?
Revenue
78.5m
USD
Based on the financial report for Dec 31, 2023, Arvinas Inc's Revenue amounts to 78.5m USD.
What is Arvinas Inc's Revenue growth rate?
Revenue CAGR 5Y
41%
Over the last year, the Revenue growth was -40%. The average annual Revenue growth rates for Arvinas Inc have been 53% over the past three years , 41% over the past five years .